Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin D Funk

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Nature Reviews. Drug Discovery|July 26, 2005
Leukotriene modifiers as potential therapeutics for cardiovascular diseaseColin D Funk
Arteriosclerosis, Thrombosis, and Vascular Biology|May 20, 2006
Lipoxygenase pathways as mediators of early inflammatory events in atherosclerosisColin D Funk
Science Translational Medicine|January 21, 2011
Leukotriene inflammatory mediators meet their matchColin D Funk
Biochemical Pharmacology|November 14, 2002
Cysteinyl leukotriene receptorsYiqun Hui, Colin D Funk
Trends in Cardiovascular Medicine|July 21, 2004
Lipoxygenase pathways in atherogenesisLei Zhao, Colin D Funk
Cardiovascular Research|January 23, 2010
The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular diseaseDaniel Poeckel, Colin D Funk
Prostaglandins & Other Lipid Mediators|December 14, 2006
A novel genetic model of selective COX-2 inhibition: comparison with COX-2 null miceYing Yu, Colin D Funk
Frontiers in Pharmacology|August 28, 2020
A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting LeukotrienesColin D Funk, Ali Ardakani
Journal of Cardiovascular Pharmacology|November 22, 2007
COX-2 inhibitors and cardiovascular riskColin D Funk, Garret A FitzGerald
Prostaglandins & Other Lipid Mediators|October 7, 2009
A cell-based assay for screening lipoxygenase inhibitorsDileep G Nair, Colin D Funk
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Nature Reviews. Drug Discovery|July 26, 2005
Leukotriene modifiers as potential therapeutics for cardiovascular diseaseColin D Funk
Arteriosclerosis, Thrombosis, and Vascular Biology|May 20, 2006
Lipoxygenase pathways as mediators of early inflammatory events in atherosclerosisColin D Funk
Science Translational Medicine|January 21, 2011
Leukotriene inflammatory mediators meet their matchColin D Funk
Biochemical Pharmacology|November 14, 2002
Cysteinyl leukotriene receptorsYiqun Hui, Colin D Funk
Trends in Cardiovascular Medicine|July 21, 2004
Lipoxygenase pathways in atherogenesisLei Zhao, Colin D Funk
Cardiovascular Research|January 23, 2010
The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular diseaseDaniel Poeckel, Colin D Funk
Prostaglandins & Other Lipid Mediators|December 14, 2006
A novel genetic model of selective COX-2 inhibition: comparison with COX-2 null miceYing Yu, Colin D Funk
Frontiers in Pharmacology|August 28, 2020
A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting LeukotrienesColin D Funk, Ali Ardakani
Journal of Cardiovascular Pharmacology|November 22, 2007
COX-2 inhibitors and cardiovascular riskColin D Funk, Garret A FitzGerald
Prostaglandins & Other Lipid Mediators|October 7, 2009
A cell-based assay for screening lipoxygenase inhibitorsDileep G Nair, Colin D Funk
Pageof 10